Categories
Change Password!
Reset Password!
Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain.
Endometriosis is a chronic
condition that induces dysmenorrhea, pelvic pain and infertility resulting in
reduced quality of life in reproductive years of women. This double-blind,
randomised study focuses on determining the dose-dependent effect of elagolix
and establishes that both higher and lower dose of elagolix is effective in
reducing dysmenorrhea pelvic pain in women with endometriosis.
Endometriosis is a chronic, estrogen-dependent condition
that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide,
gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly
full estrogen suppression in previous studies.
Two similar, double-blind, randomized, 6-month phase 3
trials (Elaris Endometriosis I and II [EM-I and EM-II]) were carried out to
evaluate the effects of two doses of elagolix — 150 mg once daily (lower-dose
group) and 200 mg twice daily (higher-dose group) — as compared with placebo in
women with surgically diagnosed endometriosis and moderate or severe
endometriosis-associated pain. The two primary efficacy endpoints were the
proportion of women who had a clinical response with respect to dysmenorrhea
and the proportion who had a clinical response with respect to non-menstrual
pelvic pain at 3 months. Each of these endpoints was measured as a clinically
meaningful reduction in the pain score and a decreased or stable use of rescue
analgesic agents, as recorded in a daily electronic diary.
A total of 872 women underwent randomization in Elaris EM-I
and 817 in Elaris EM-II; of these women, 653 (74.9%) and 632 (77.4%),
respectively, completed the intervention. At 3 months, a significantly greater
proportion of women who received each elagolix dose met the clinical response
criteria for the two primary endpoints than did those who received placebo. In
Elaris EM-I, the percentage of women who had a clinical response with respect
to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the
higher-dose elagolix group, as compared with 19.6% in the placebo group; in
Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared
with 22.7% (P<0.001 for all comparisons). In Elaris EM-I, the percentage of
women who had a clinical response with respect to nonmenstrual pelvic pain was
50.4% in the lower-dose elagolix group and 54.5% in the higher-dose elagolix
group, as compared with 36.5% in the placebo group (P<0.001 for all comparisons);
in Elaris EM-II, the corresponding percentages were 49.8% and 57.8%, as
compared with 36.5% (P=0.003 and P<0.001, respectively). The responses with
respect to dysmenorrhea and nonmenstrual pelvic pain were sustained at 6
months. Women who received elagolix had higher rates of hot flushes (mostly
mild or moderate), higher levels of serum lipids, and greater decreases from
baseline in bone mineral density than did those who received placebo; there
were no adverse endometrial findings.
Both higher and lower doses of elagolix were effective in
improving dysmenorrhea and nonmenstrual pelvic pain during a 6-month period in
women with endometriosis-associated pain. The two doses of elagolix were
associated with hypoestrogenic adverse effects.
N Engl J Med. 2017 Jul 6;377(1):28-40
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Hugh S et al.
Comments (0)